ABT-494: Eczema Study


STUDY BASICS

Have you been diagnosed with moderate to severe eczema? Are you ages 18-75? If so, you may be eligible to participate in a study to help researchers evaluate an investigational drug called upadacitinib, which is being tested as a treatment for several inflammatory diseases, including eczema. Compensation provided.


IRB:
  33342/25B - A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitnib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

RELATED STUDIES

ABT-494: Eczema Study [Pediatric] (33342/25A)


Age Range
AGE:   18 - 75

Duration VISITS:  multiple

Location LOCATION: 
Falk Medical Building - Oakland

Compensation COMPENSATION: 
$80.00 per visit
I'M INTERESTED
SHARE STUDY
Email A FriendEmail A Friend   FacebookFacebook   TwitterTwitter   Linked-InLinked-In

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.





Pitt+Me

This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.